The DEA Wants 57 Times More Ibogaine Made for Research Next Year
The Drug Enforcement Administration has proposed sharply higher 2027 production limits for several psychedelics used in research, Marijuana Moment's Tom Angell reports. The biggest jump is for ibogaine: from 210 grams this year to 12,002 grams, about 57 times more. MDMA would rise from 12,000 to 33,296 grams, psilocybin from 50,000 to 60,000 grams, and psilocin, the compound psilocybin turns into in the body, from 80,000 to 93,600 grams.
The DEA says the MDMA and ibogaine increases are for research and clinical trials in conditions including PTSD and depression, and that they "align with" President Trump's April executive order on psychedelic research. These quotas cap how much of each Schedule I drug can legally be manufactured in the U.S. each year, so they set a ceiling on how many trials can run. The notice is due in the Federal Register this week, followed by a 30-day public comment period.
For ibogaine, it's a sign of how fast the compound has moved from a niche to a research priority, with state-funded programs in Texas and Arizona and private money such as Sergey Brin's backing of the startup Soneira, covered in this week's People Series. Our ibogaine deep dive covers the cardiac risks those trials have to manage. Active ibogaine and MDMA trials are on our trials tracker.